Characterization of hepatic cytochrome P4503A activity in patients with end‐stage renal disease
- 17 May 2003
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 73 (5) , 427-434
Abstract
Background: The cytochrome P450 (CYP) oxidative enzyme system, located primarily in the liver and small intestine, is responsible for metabolism and detoxification of numerous endogenous and exogenous substances. The most abundant CYP enzyme, CYP3A, is known to be involved in the metabolism of more than 200 commonly used medications. In experimental models of renal failure, both hepatic function and CYP enzyme content are reduced; however, direct evidence in humans is lacking. Evaluation of drug metabolism in patients with end‐stage renal disease is important because these patients use a large number of medications and are at risk of adverse reactions and drug‐drug interactions.Methods: We measured hepatic CYP3A activity at baseline and after rifampin (INN, rifampicin) enzyme induction in 12 patients with end‐stage renal disease and 12 healthy, age‐matched controls. Hepatic CYP3A phenotype was characterized with the erythromycin breath test, and enzyme induction capacity was evaluated with a short course of rifampin (600 mg/d for 6 days).Results: The end‐stage renal disease group had 28% lower baseline erythromycin breath test values than controls (P < .05); however, enzyme induction capacity after rifampin administration was similar between groups (P = .70).Conclusion: The findings suggested that one mechanism by which patients with end‐stage renal disease are at increased risk of drug toxicity is reduced activity of the CYP3A enzyme pathway.Clinical Pharmacology & Therapeutics (2003) 73, 427–434; doi: 10.1016/S0009‐9236(03)00056‐0Keywords
This publication has 30 references indexed in Scilit:
- Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin AntibacterialsClinical Pharmacokinetics, 2001
- Pharmacokinetics of Single‐Dose Reboxetine in Volunteers with Renal InsufficiencyThe Journal of Clinical Pharmacology, 2000
- Ritonavir Enables Combined Therapy with Rifampin and SaquinavirClinical Infectious Diseases, 1999
- Effect of Multiple Doses of Rifampin on the [14C N‐methyl] Erythromycin Breath Test in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1998
- Changes of Hepatic Microsomal Oxidative Drug Metabolizing Enzymes in Chronic Renal Failure (CRF) Rats by Partial NephrectomyThe Japanese Journal of Pharmacology, 1995
- The Human Hepatic Cytochromes P450 Involved in Drug MetabolismCritical Reviews in Toxicology, 1992
- Clinical Pharmacokinetic Properties of the Macrolide AntibioticsClinical Pharmacokinetics, 1989
- The effect of peroxisome proliferators on the metabolism and spectral interaction of endogenous substrates of cytochrome P-450 in rat hepatic microsomesLife Sciences, 1984
- Induction of laurate ω-hydroxylase by di (2-ethylhexyl)phthalate in rat liver microsomesBiochemical and Biophysical Research Communications, 1984
- Pharmacokinetics of Nitrendipine in Patients with Renal FailureJournal of Cardiovascular Pharmacology, 1984